Colorectal CancerNCT07842692
Serum Endocan Levels in Colorectal Cancer
An observational study of Colorectal Cancer, run by Assiut University.
Trial summary
This case-control study aims to measure serum endocan levels in patients with colorectal cancer and healthy controls using ELISA and to compare the levels between the two groups. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer
- How many people
- 64 participants
- Where
- No sites listed yet
- Study dates
- 26 Sep 2026to 25 Feb 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults with newly diagnosed colorectal cancer and age- and sex-matched healthy volunteers at South Egypt Cancer Institute, Assiut University.
Who may be able to join
- - Age 18 years or older
- Newly diagnosed colorectal cancer confirmed by histopathology (cases)
- No previous surgery, chemotherapy, or radiotherapy for colorectal cancer
- Healthy adults with no history of cancer or inflammatory bowel disease (controls)
- Written informed consent
Who cannot join
- - Previous malignancy
- Previous chemotherapy or radiotherapy for colorectal cancer
- Active infection
- Autoimmune disease
- Chronic liver disease
- Chronic kidney disease
- Pregnancy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Serum Endocan Levels Measured by ELISA in Colorectal Cancer: Relation to Clinicopathological Features
This case-control study aims to measure serum endocan levels in patients with colorectal cancer and healthy controls using ELISA and to compare the levels between the two groups.
Read the detailed description
Colorectal cancer is a major cause of cancer-related morbidity and mortality. Circulating biomarkers such as endocan may provide useful information about disease characteristics.
This observational study will include newly diagnosed colorectal cancer patients and age- and sex-matched healthy controls. Serum endocan levels will be measured by enzyme-linked immunosorbent assay (ELISA) before any treatment.
- Conditions
- Colorectal Cancer
- Keywords
- Endocan, Assiut, ELISA, Colorectal cancer, Biomarker
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Colorectal Cancer | Patients with newly diagnosed colorectal cancer confirmed by histopathology. | |
| Healthy Controls | Apparently healthy volunteers matched for age and sex with no history of malignant disease. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean serum endocan level
Mean serum endocan concentration (ng/mL) measured by ELISA in colorectal cancer patients compared with healthy controls.
Measured: Baseline
Secondary outcomes (4)
Serum endocan level according to tumor stage
Mean serum endocan concentration according to TNM tumor stage.
Measured: Baseline
Serum endocan level according to histological grade
Mean serum endocan concentration according to histological grade.
Measured: Baseline
Serum endocan level according to lymph node status
Mean serum endocan concentration in patients with and without lymph node involvement.
Measured: Baseline
Serum endocan level according to distant metastasis
Mean serum endocan concentration in patients with and without distant metastasis.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start26 Sep 2026 (estimated)
- Primary completion26 Sep 2027 (estimated)
- Study completion25 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 64 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mariam Dous Mohany Dous, Assiut University
- Investigators
- Eman H Ahmed, prof, Study chair, Oncological Clinical Pathology South Egypt Cancer Institute, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07842692
- Sponsor's protocol ID
- Endocan-CRC-Assiut-2026
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum Endocan Levels Measured by ELISA in Colorectal Cancer: Relation to Clinicopathological Features
- ClinicalTrials.gov ID
- NCT07842692
- Acronym / sponsor ID
- Endocan-CRC-Assiut-2026
- Conditions
- Colorectal Cancer
- Keywords
- Endocan, Assiut, ELISA, Colorectal cancer, Biomarker
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 64 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 26 Sep 2026 (estimated)
- Primary completion
- 26 Sep 2027 (estimated)
- Study completion
- 25 Feb 2028 (estimated)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This case-control study aims to measure serum endocan levels in patients with colorectal cancer and healthy controls using ELISA and to compare the levels between the two groups.
Detailed description
Colorectal cancer is a major cause of cancer-related morbidity and mortality. Circulating biomarkers such as endocan may provide useful information about disease characteristics.
This observational study will include newly diagnosed colorectal cancer patients and age- and sex-matched healthy controls. Serum endocan levels will be measured by enzyme-linked immunosorbent assay (ELISA) before any treatment.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Colorectal Cancer | – | –Patients with newly diagnosed colorectal cancer confirmed by histopathology. |
| Healthy Controls | – | –Apparently healthy volunteers matched for age and sex with no history of malignant disease. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with newly diagnosed colorectal cancer and age- and sex-matched healthy volunteers at South Egypt Cancer Institute, Assiut University.
Key inclusion criteria (5 listed)
- - Age 18 years or older
- Newly diagnosed colorectal cancer confirmed by histopathology (cases)
- No previous surgery, chemotherapy, or radiotherapy for colorectal cancer
- Healthy adults with no history of cancer or inflammatory bowel disease (controls)
- Written informed consent
Key exclusion criteria (7 listed)
- - Previous malignancy
- Previous chemotherapy or radiotherapy for colorectal cancer
- Active infection
- Autoimmune disease
- Chronic liver disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mean serum endocan level
Time frame: Baseline
Mean serum endocan concentration (ng/mL) measured by ELISA in colorectal cancer patients compared with healthy controls.
4 secondary outcomes
Serum endocan level according to tumor stage
Time frame: Baseline
Serum endocan level according to histological grade
Time frame: Baseline
Serum endocan level according to lymph node status
Time frame: Baseline
Serum endocan level according to distant metastasis
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eman H Ahmed, prof study chair
Oncological Clinical Pathology South Egypt Cancer Institute, Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mariam D Mohany (+20 12 29902407, mariamdous278@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean serum endocan level (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026; AzTrials last refreshed its copy on 7 Nov 2026.